- Home
- HAE vs OCUL Comparison
HAE vs OCUL Comparison
Compare HAE & OCUL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HAE
- OCUL
- Stock Information
- Founded
- HAE 1971
- OCUL 2006
- Country
- HAE United States
- OCUL United States
- Employees
- HAE N/A
- OCUL N/A
- Industry
- HAE Medical/Dental Instruments
- OCUL Biotechnology: Pharmaceutical Preparations
- Sector
- HAE Health Care
- OCUL Health Care
- Exchange
- HAE Nasdaq
- OCUL Nasdaq
- Market Cap
- HAE 2.5B
- OCUL 2.3B
- IPO Year
- HAE 1991
- OCUL 2014
- Fundamental
- Price
- HAE $71.92
- OCUL $11.16
- Analyst Decision
- HAE Strong Buy
- OCUL Strong Buy
- Analyst Count
- HAE 9
- OCUL 10
- Target Price
- HAE $79.67
- OCUL $22.33
- AVG Volume (30 Days)
- HAE 949.3K
- OCUL 2.2M
- Earning Date
- HAE 11-06-2025
- OCUL 11-04-2025
- Dividend Yield
- HAE N/A
- OCUL N/A
- EPS Growth
- HAE 42.54
- OCUL N/A
- EPS
- HAE 3.44
- OCUL N/A
- Revenue
- HAE $1,327,850,000.00
- OCUL $55,783,000.00
- Revenue This Year
- HAE N/A
- OCUL N/A
- Revenue Next Year
- HAE $6.35
- OCUL $17.75
- P/E Ratio
- HAE $20.88
- OCUL N/A
- Revenue Growth
- HAE N/A
- OCUL N/A
- 52 Week Low
- HAE $47.32
- OCUL $5.79
- 52 Week High
- HAE $94.99
- OCUL $13.85
- Technical
- Relative Strength Index (RSI)
- HAE 87.25
- OCUL 46.28
- Support Level
- HAE $49.96
- OCUL $10.30
- Resistance Level
- HAE $71.37
- OCUL $12.10
- Average True Range (ATR)
- HAE 2.27
- OCUL 0.44
- MACD
- HAE 2.60
- OCUL -0.04
- Stochastic Oscillator
- HAE 96.93
- OCUL 49.72
About HAE Haemonetics Corporation
Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The company primarily emphasizes its plasma and hospital segments due to their robust growth potential, whereas the blood center segment tends to be constrained by higher competition. Product revenue is driven by demand for disposable blood component collection and processing sets and the related equipment needed for proper functionality.
About OCUL Ocular Therapeutix Inc.
Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT.